Literature DB >> 17367825

The mu opioid receptor is involved in buprenorphine-induced locomotor stimulation and conditioned place preference.

Paul Marquez1, Ramkumarie Baliram, Brigitte L Kieffer, Kabirullah Lutfy.   

Abstract

The analgesic effect of buprenorphine is mediated via the mu opioid receptor (MOP). In the present study, using mice lacking the MOP and their wild-type littermates, we determined the role of the MOP in buprenorphine-induced locomotor stimulation and conditioned place preference (CPP). Buprenorphine (3 mg/kg) increased motor activity in wild-type but not in MOP knockout mice, showing the motor stimulatory action of buprenorphine is mediated via the MOP. When the mice were given the same treatment once daily for 5 consecutive days and challenged with buprenorphine on day 11, the motor stimulatory action of buprenorphine was enhanced in wild-type but not in MOP knockout mice, showing sensitization developed to the motor stimulatory action of buprenorphine and this phenomenon was mediated via the MOP. Likewise, buprenorphine induced CPP in wild-type mice after four alternate-day saline/buprenorphine (3 mg/kg) injections paired with olfactory and visual cues. However, buprenorphine failed to induce CPP in MOP knockout mice. In contrast, amphetamine (1 mg/kg) induced a comparable CPP in wild-type and MOP knockout mice. Together, the present results suggest that the ability of buprenorphine to increase motor activity and induce locomotor sensitization and CPP is mediated via the MOP.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17367825      PMCID: PMC2267901          DOI: 10.1016/j.neuropharm.2007.01.005

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  43 in total

Review 1.  Conditioned place preference: what does it add to our preclinical understanding of drug reward?

Authors:  M T Bardo; R A Bevins
Journal:  Psychopharmacology (Berl)       Date:  2000-12       Impact factor: 4.530

2.  The effects of long-term chronic buprenorphine treatment on the locomotor and nucleus accumbens dopamine response to acute heroin and cocaine in rats.

Authors:  Robert E Sorge; Jane Stewart
Journal:  Pharmacol Biochem Behav       Date:  2006-06-27       Impact factor: 3.533

3.  Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine.

Authors:  Paul Marquez; Ramkumarie Baliram; Nagaraju Gajawada; Theodore C Friedman; Kabirullah Lutfy
Journal:  Behav Neurosci       Date:  2006-02       Impact factor: 1.912

4.  Kappa antagonist effects of buprenorphine in the rat drug-discrimination procedure.

Authors:  S S Negus; M J Picker; L A Dykstra
Journal:  NIDA Res Monogr       Date:  1989

5.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog.

Authors:  W R Martin; C G Eades; J A Thompson; R E Huppler; P E Gilbert
Journal:  J Pharmacol Exp Ther       Date:  1976-06       Impact factor: 4.030

6.  Delta opioid antagonist effects of buprenorphine in rhesus monkeys.

Authors:  S S Negus; J M Bidlack; N K Mello; M S Furness; K C Rice; M R Brandt
Journal:  Behav Pharmacol       Date:  2002-11       Impact factor: 2.293

Review 7.  Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction.

Authors:  Thomas M Tzschentke
Journal:  Psychopharmacology (Berl)       Date:  2002-03-06       Impact factor: 4.530

8.  Buprenorphine: differential interaction with opiate receptor subtypes in vivo.

Authors:  W Sadée; J S Rosenbaum; A Herz
Journal:  J Pharmacol Exp Ther       Date:  1982-10       Impact factor: 4.030

9.  Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats.

Authors:  G Di Chiara; A Imperato
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

10.  Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors.

Authors:  J Kamei; A Saitoh; T Suzuki; M Misawa; H Nagase; Y Kasuya
Journal:  Life Sci       Date:  1995-03-03       Impact factor: 5.037

View more
  20 in total

1.  The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.

Authors:  Taline V Khroyan; Willma E Polgar; Gerta Cami-Kobeci; Stephen M Husbands; Nurulain T Zaveri; Lawrence Toll
Journal:  J Pharmacol Exp Ther       Date:  2010-12-21       Impact factor: 4.030

2.  Buprenorphine is a weak partial agonist that inhibits opioid receptor desensitization.

Authors:  Michael S Virk; Seksiri Arttamangkul; William T Birdsong; John T Williams
Journal:  J Neurosci       Date:  2009-06-03       Impact factor: 6.167

3.  Antidepressant-like effects of BU10119, a novel buprenorphine analogue with mixed κ/μ receptor antagonist properties, in mice.

Authors:  Abdulrahman Almatroudi; Mehrnoosh Ostovar; Christopher P Bailey; Stephen M Husbands; Sarah J Bailey
Journal:  Br J Pharmacol       Date:  2017-11-06       Impact factor: 8.739

4.  Heteromers of μ opioid and dopamine D1 receptors modulate opioid-induced locomotor sensitization in a dopamine-independent manner.

Authors:  Yi-Min Tao; Chuan Yu; Wei-Sheng Wang; Yuan-Yuan Hou; Xue-Jun Xu; Zhi-Qiang Chi; Yu-Qiang Ding; Yu-Jun Wang; Jing-Gen Liu
Journal:  Br J Pharmacol       Date:  2017-07-18       Impact factor: 8.739

Review 5.  Targeting opioid dysregulation in depression for the development of novel therapeutics.

Authors:  Caroline A Browne; Irwin Lucki
Journal:  Pharmacol Ther       Date:  2019-04-30       Impact factor: 12.310

6.  Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.

Authors:  Lawrence Toll; Taline V Khroyan; Willma E Polgar; Faming Jiang; Cris Olsen; Nurulain T Zaveri
Journal:  J Pharmacol Exp Ther       Date:  2009-09-22       Impact factor: 4.030

Review 7.  Reward processing by the opioid system in the brain.

Authors:  Julie Le Merrer; Jérôme A J Becker; Katia Befort; Brigitte L Kieffer
Journal:  Physiol Rev       Date:  2009-10       Impact factor: 37.312

8.  Effects of buprenorphine on behavioral tests for antidepressant and anxiolytic drugs in mice.

Authors:  Edgardo Falcon; Kaitlyn Maier; Shivon A Robinson; Tiffany E Hill-Smith; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2014-09-03       Impact factor: 4.530

9.  The role of the opioid receptor-like (ORL1) receptor in motor stimulatory and rewarding actions of buprenorphine and morphine.

Authors:  P Marquez; J Borse; A T Nguyen; A Hamid; K Lutfy
Journal:  Neuroscience       Date:  2008-06-19       Impact factor: 3.590

Review 10.  15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse.

Authors:  Pauline Charbogne; Brigitte L Kieffer; Katia Befort
Journal:  Neuropharmacology       Date:  2013-09-10       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.